Trials / Terminated
TerminatedNCT00123942
Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
Phase I Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (estimated)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) and safety and tolerability of MEDI-507 in patients with CD2-positive lymphoproliferative disorders.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI-507 |
Timeline
- Start date
- 2004-04-01
- First posted
- 2005-07-26
- Last updated
- 2007-06-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00123942. Inclusion in this directory is not an endorsement.